Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade
Antigen-presenting cells (APCs) are pivotal mediators of immune responses. Their role has increasingly been spotlighted in the realm of cancer immunology, particularly as our understanding of immunotherapy continues to evolve and improve. There is growing evidence that these cells play a non-trivial...
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Springer Netherlands
2024
|
| Online Access: | https://hdl.handle.net/1721.1/153424 |
| _version_ | 1826199510193274880 |
|---|---|
| author | Wang, Cassia Chen, Lee Fu, Doris Liu, Wendi Puri, Anusha Kellis, Manolis Yang, Jiekun |
| author2 | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory |
| author_facet | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory Wang, Cassia Chen, Lee Fu, Doris Liu, Wendi Puri, Anusha Kellis, Manolis Yang, Jiekun |
| author_sort | Wang, Cassia |
| collection | MIT |
| description | Antigen-presenting cells (APCs) are pivotal mediators of immune responses. Their role has increasingly been spotlighted in the realm of cancer immunology, particularly as our understanding of immunotherapy continues to evolve and improve. There is growing evidence that these cells play a non-trivial role in cancer immunity and have roles dependent on surface markers, growth factors, transcription factors, and their surrounding environment. The main dendritic cell (DC) subsets found in cancer are conventional DCs (cDC1 and cDC2), monocyte-derived DCs (moDC), plasmacytoid DCs (pDC), and mature and regulatory DCs (mregDC). The notable subsets of monocytes and macrophages include classical and non-classical monocytes, macrophages, which demonstrate a continuum from a pro-inflammatory (M1) phenotype to an anti-inflammatory (M2) phenotype, and tumor-associated macrophages (TAMs). Despite their classification in the same cell type, each subset may take on an immune-activating or immunosuppressive phenotype, shaped by factors in the tumor microenvironment (TME). In this review, we introduce the role of DCs, monocytes, and macrophages and recent studies investigating them in the cancer immunity context. Additionally, we review how certain characteristics such as abundance, surface markers, and indirect or direct signaling pathways of DCs and macrophages may influence tumor response to immune checkpoint blockade (ICB) therapy. We also highlight existing knowledge gaps regarding the precise contributions of different myeloid cell subsets in influencing the response to ICB therapy. These findings provide a summary of our current understanding of myeloid cells in mediating cancer immunity and ICB and offer insight into alternative or combination therapies that may enhance the success of ICB in cancers. |
| first_indexed | 2024-09-23T11:21:04Z |
| format | Article |
| id | mit-1721.1/153424 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T11:21:04Z |
| publishDate | 2024 |
| publisher | Springer Netherlands |
| record_format | dspace |
| spelling | mit-1721.1/1534242024-07-12T16:21:46Z Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade Wang, Cassia Chen, Lee Fu, Doris Liu, Wendi Puri, Anusha Kellis, Manolis Yang, Jiekun Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory Massachusetts Institute of Technology. Department of Biological Engineering Antigen-presenting cells (APCs) are pivotal mediators of immune responses. Their role has increasingly been spotlighted in the realm of cancer immunology, particularly as our understanding of immunotherapy continues to evolve and improve. There is growing evidence that these cells play a non-trivial role in cancer immunity and have roles dependent on surface markers, growth factors, transcription factors, and their surrounding environment. The main dendritic cell (DC) subsets found in cancer are conventional DCs (cDC1 and cDC2), monocyte-derived DCs (moDC), plasmacytoid DCs (pDC), and mature and regulatory DCs (mregDC). The notable subsets of monocytes and macrophages include classical and non-classical monocytes, macrophages, which demonstrate a continuum from a pro-inflammatory (M1) phenotype to an anti-inflammatory (M2) phenotype, and tumor-associated macrophages (TAMs). Despite their classification in the same cell type, each subset may take on an immune-activating or immunosuppressive phenotype, shaped by factors in the tumor microenvironment (TME). In this review, we introduce the role of DCs, monocytes, and macrophages and recent studies investigating them in the cancer immunity context. Additionally, we review how certain characteristics such as abundance, surface markers, and indirect or direct signaling pathways of DCs and macrophages may influence tumor response to immune checkpoint blockade (ICB) therapy. We also highlight existing knowledge gaps regarding the precise contributions of different myeloid cell subsets in influencing the response to ICB therapy. These findings provide a summary of our current understanding of myeloid cells in mediating cancer immunity and ICB and offer insight into alternative or combination therapies that may enhance the success of ICB in cancers. 2024-01-30T17:36:40Z 2024-01-30T17:36:40Z 2024-01-23 2024-01-28T04:21:59Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/153424 Wang, C., Chen, L., Fu, D. et al. Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade. Clin Exp Metastasis (2024). PUBLISHER_CC en https://doi.org/10.1007/s10585-023-10257-z Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ The Author(s) application/pdf Springer Netherlands Springer Netherlands |
| spellingShingle | Wang, Cassia Chen, Lee Fu, Doris Liu, Wendi Puri, Anusha Kellis, Manolis Yang, Jiekun Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade |
| title | Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade |
| title_full | Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade |
| title_fullStr | Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade |
| title_full_unstemmed | Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade |
| title_short | Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade |
| title_sort | antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade |
| url | https://hdl.handle.net/1721.1/153424 |
| work_keys_str_mv | AT wangcassia antigenpresentingcellsincancerimmunityandmediationofimmunecheckpointblockade AT chenlee antigenpresentingcellsincancerimmunityandmediationofimmunecheckpointblockade AT fudoris antigenpresentingcellsincancerimmunityandmediationofimmunecheckpointblockade AT liuwendi antigenpresentingcellsincancerimmunityandmediationofimmunecheckpointblockade AT purianusha antigenpresentingcellsincancerimmunityandmediationofimmunecheckpointblockade AT kellismanolis antigenpresentingcellsincancerimmunityandmediationofimmunecheckpointblockade AT yangjiekun antigenpresentingcellsincancerimmunityandmediationofimmunecheckpointblockade |